Alice C Levine, MD Email Alice Levine
Endocrine, Diabetes and Bone Diseases (Endocrinology)
Mount Sinai Doctors
?
-
- Positions
- PROFESSOR | Medicine, Endocrinology, Diabetes and Bone Disease
- ASSOCIATE PROFESSOR | Oncological Sciences
-
- Specialty
- Endocrine, Diabetes and Bone Diseases (Endocrinology)
-
- Language
- English
-
- Hospital Affiliations
- The Mount Sinai Hospital
- New York Eye and Ear Infirmary of Mount Sinai
- Mount Sinai Beth Israel
-
- Phone
- Department of Medicine-Endocrinology 212-241-3422 212-241-3422
- Neurosurgery 212-241-3422 212-241-3422
Patient Experience Rating
5 Stars
Book an Appointment - Alice C Levine, MD
Dr. Alice Levine has been a faculty member of the Mount Sinai School of Medicine since 1986 when she completed her Fellowship in Endocrinology and Metabolism. She divides her time between clinical, teaching and research activities. Her clinical interests are diseases of the adrenal, pituitary and reproductive glands with an emphasis on hormone-dependent neoplasias. She publishes extensively in these fields. She is the Course Director for the Second Year Medical School Endocrine Pathophysiology Course and is often cited as one of the outstanding Faculty Teachers by Medical Students, Residents and Fellows. In her role as the Program Director of the Endocrine Fellowship, she mentors students, trainees and faculty in clinical and basic science research.
Certifications
American Board of Endocrinology
American Board of Internal Medicine
Clinical Focus
- Acromegaly
- Addison's Disease
- Adrenal Crisis
- Adrenal Incidentaloma
- Adrenocortical Carcinoma
- Congenital Adrenal Hyperplasia
- Cushing's Syndrome
- Galactorrhea
- Pheochromocytoma
- Pituitary Adenoma
- Pituitary Cyst
- Pituitary Tumor
Education
MD, Columbia University College of Physicians & Surgeons
Internship, Internal Medicine
Manhattan VA Hospital
Residency, Internal Medicine
Manhattan VA Hospital
Fellowship, Endocrinology
Mount Sinai Hospital
Language
English
Interactive roles of androgens and growth factors in human prostate development and neoplasia
Interactive roles of androgens and growth factors in human
prostate development and neoplasia
Dr. Levine’s Research Laboratory focuses on understanding how hormones and growth factors coordinately regulate prostate growth in order to develop new treatment strategies for men with prostatic disorders. Co-directed by Dr. Alexander Kirschenbaum, Clinical Associate Professor of Urology, her group was the first to publish on the successful management of benign prostatic hyperplasia with hormonal therapy. They also reported that androgens increase stromal cell growth in the prostate and also regulate the powerful angiogenic factor, vascular endothelial cell growth factor (VEGF). Dr. Levine’s group were also among the first to determine the cell-specific expression of cyclooxygenase-2 (COX-2) in the human prostate and to report that selective COX-2 inhibitors kill prostate cancer cells in vitro and in vivo. They established the role of COX-2 in hypoxia mediated upregulation of survival and angiogenic proteins in human prostate cancer cells. Dr. Levine’s group recently isolated and characterized a protein derived from dietary bitter melon seeds that selectively kills pre-neoplastic and neoplastic prostate cancer cells. Her group has also published extensively on the mechanisms underlying prostate cancer bone metastases and developed a bone-targeting compound aimed at preventing and treating prostate cancer bone metastases.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Levine did not report having any of the following types of financial relationships with industry during 2020 and/or 2021: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website.
Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.